Pronounced cancer resistance in a subterranean rodent, the blind mole-rat, Spalax: In vivo and in vitro evidence

BMC Biology

Volumn 11, Issue , 2013, Pages

  Manov, Irena ^a   Hirsh, Mark ^b   Iancu, Theodore C ^c   Malik, Assaf ^a   Sotnichenko, Nick ^a   Band, Mark ^d   Avivi, Aaron ^a   Shams, Imad ^a  

^a UNIVERSITY OF HAIFA   (Israel)

^b ASSAF HAROFEH MEDICAL CENTER   (Israel)

^c Milman David Foundation for Pediatric Research   (Israel)

^d UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; CARCINOGEN; PHORBOL 13 ACETATE 12 MYRISTATE;

ANIMAL; ARTICLE; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CELL SHAPE; CELL SURVIVAL; COCULTURE; CULTURE MEDIUM; DISEASE RESISTANCE; DNA FRAGMENTATION; DRUG EFFECT; DRUG SCREENING; FIBROBLAST; FIBROSARCOMA; HUMAN; IMMUNOLOGY; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; MITOCHONDRIAL DYNAMICS; MOLE RAT; MOUSE; NEOPLASM; PATHOLOGY; RAT; TUMOR CELL LINE;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; CARCINOGENS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SHAPE; CELL SURVIVAL; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; DISEASE RESISTANCE; DNA FRAGMENTATION; FIBROBLASTS; FIBROSARCOMA; HUMANS; LIVER NEOPLASMS; MICE; MITOCHONDRIAL DYNAMICS; NEOPLASMS; RATS; SPALAX; TETRADECANOYLPHORBOL ACETATE; TUMOR STEM CELL ASSAY;

EID: 84881538108     PISSN: None     EISSN: 17417007     Source Type: Journal    
DOI: 10.1186/1741-7007-11-91     Document Type: Article

References (56)

1. Nevo E, Ivanitskaya E, Beiles A. Adaptive Radiation of Blind Subterranean Mole Rats 2001, Leiden: Backhuys.
2. Shams I, Avivi A, Nevo E. Oxygen and carbon dioxide fluctuations in burrows of subterranean blind mole rats indicate tolerance to hypoxic-hypercapnic stresses. Comp Biochem Physiol A Mol Integr Physiol 2005, 142:376-382. 10.1016/j.cbpa.2005.09.003, 16223592.
3. Ravid O, Shams I, Ben Califa N, Nevo E, Avivi A, Neumann D. An extracellular region of the erythropoietin receptor of the subterranean blind mole rat Spalax enhances receptor maturation. Proc Natl Acad Sci U S A 2007, 104:14360-14365. 10.1073/pnas.0706777104, 1964849, 17724331.
4. Schulke S, Dreidax D, Malik A, Burmester T, Nevo E, Band M, Avivi A, Hankeln T. Living with stress: regulation of antioxidant defense genes in the subterranean, hypoxia-tolerant mole rat, Spalax. Gene 2012, 500:199-206. 10.1016/j.gene.2012.03.019, 22441129.
5. Shams I, Nevo E, Avivi A. Ontogenetic expression of erythropoietin and hypoxia-inducible factor-1 alpha genes in subterranean blind mole rats. FASEB J 2005, 19:307-309.
6. Avivi A, Gerlach F, Joel A, Reuss S, Burmester T, Nevo E, Hankeln T. Neuroglobin, cytoglobin, and myoglobin contribute to hypoxia adaptation of the subterranean mole rat Spalax. Proc Natl Acad Sci U S A 2010, 107:21570-21575. 10.1073/pnas.1015379107, 3003035, 21115824.
7. Avivi A, Shams I, Joel A, Lache O, Levy AP, Nevo E. Increased blood vessel density provides the mole rat physiological tolerance to its hypoxic subterranean habitat. FASEB J 2005, 19:1314-1316.
8. Avivi A, Ashur-Fabian O, Joel A, Trakhtenbrot L, Adamsky K, Goldstein I, Amariglio N, Rechavi G, Nevo E. P53 in blind subterranean mole rats-loss-of-function versus gain-of-function activities on newly cloned Spalax target genes. Oncogene 2007, 26:2507-2512. 10.1038/sj.onc.1210045, 17043642.
9. Nasser NJ, Avivi A, Shafat I, Edovitsky E, Zcharia E, Ilan N, Vlodavsky I, Nevo E. Alternatively spliced Spalax heparanase inhibits extracellular matrix degradation, tumor growth, and metastasis. Proc Natl Acad Sci U S A 2009, 106:2253-2258. 10.1073/pnas.0812846106, 2650141, 19164514.
10. Malik A, Korol A, Hubner S, Hernandez AG, Thimmapuram J, Ali S, Glaser F, Paz A, Avivi A, Band M. Transcriptome sequencing of the blind subterranean mole rat, Spalax galili: utility and potential for the discovery of novel evolutionary patterns. PLoS One 2011, 6:e21227. 10.1371/journal.pone.0021227, 3155515, 21857902.
11. Malik A, Korol A, Weber M, Hankeln T, Avivi A, Band M. Transcriptome analysis of the Spalax hypoxia survival response includes suppression of apoptosis and tight control of angiogenesis. BMC Genomics 2012, 13:615. 10.1186/1471-2164-13-615, 3533650, 23148642.
12. Bremnes RM, Donnem T, Al-Saad S, Al-Shibli K, Andersen S, Sirera R, Camps C, Marinez I, Busund LT. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thoracic Oncol Off Pub Int Assoc Study Lung Cancer 2011, 6:209-217.
13. Egeblad M, Nakasone ES, Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Dev Cell 2010, 18:884-901. 10.1016/j.devcel.2010.05.012, 2905377, 20627072.
14. Angeli F, Koumakis G, Chen MC, Kumar S, Delinassios JG. Role of stromal fibroblasts in cancer: promoting or impeding?. Tumour Biol 2009, 30:109-120. 10.1159/000218708, 19440007.
15. Dotto GP, Weinberg RA, Ariza A. Malignant transformation of mouse primary keratinocytes by Harvey sarcoma virus and its modulation by surrounding normal cells. Proc Natl Acad Sci U S A 1988, 85:6389-6393. 10.1073/pnas.85.17.6389, 281977, 2457913.
16. Proia DA, Kuperwasser C. Stroma: tumor agonist or antagonist. Cell Cycle 2005, 4:1022-1025. 10.4161/cc.4.8.1903, 16082203.
17. Goerttler K, Loehrke H, Hesse B, Schweizer J. Skin tumor formation in the European hamster (Cricetus cricetus L.) after topical initiation with 7,12-dimethylbenz[a]anthracene (DMBA) and promotion with 12-O-tetradecanoylphorbol-13-acetate (TPA). Carcinogenesis 1984, 5:521-524. 10.1093/carcin/5.4.521, 6423310.
18. de Visser KE, Coussens LM. The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol 2006, 13:118-137.
19. Goerttler K, Loehrke H, Schweizer J, Hesse B. Diterpene ester-mediated two-stage carcinogenesis. Carcinog Compr Surv 1982, 7:75-83.
20. Krelin Y, Voronov E, Dotan S, Elkabets M, Reich E, Fogel M, Huszar M, Iwakura Y, Segal S, Dinarello CA, Apte RN. Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res 2007, 67:1062-1071. 10.1158/0008-5472.CAN-06-2956, 17283139.
21. Antonescu CR, Baren A. Spectrum of low-grade fibrosarcomas: a comparative ultrastructural analysis of low-grade myxofibrosarcoma and fibromyxoid sarcoma. Ultrastruct Pathol 2004, 28:321-332. 10.1080/019131290882259, 15764580.
22. Buffenstein R. Negligible senescence in the longest living rodent, the naked mole-rat: insights from a successfully aging species. J Comp Physiol B 2008, 178:439-445. 10.1007/s00360-007-0237-5, 18180931.
23. Shams I, Avivi A, Nevo E. Hypoxic stress tolerance of the blind subterranean mole rat: expression of erythropoietin and hypoxia-inducible factor 1 alpha. Proc Natl Acad Sci U S A 2004, 101:9698-9703. 10.1073/pnas.0403540101, 470738, 15210955.
24. Avivi A, Ashur-Fabian O, Amariglio N, Nevo E, Rechavi G. p53 - a key player in tumoral and evolutionary adaptation: a lesson from the Israeli blind subterranean mole rat. Cell Cycle 2005, 4:368-372. 10.4161/cc.4.3.1534, 15701965.
25. Yuspa SH. The pathogenesis of squamous cell cancer: lessons learned from studies of skin carcinogenesis. J Dermatol Sci 1998, 17:1-7. 10.1016/S0923-1811(97)00071-6, 9651822.
26. Izzotti A, Camoirano A, Cartiglia C, Grubbs CJ, Lubet RA, Kelloff GJ, De Flora S. Patterns of DNA adduct formation in liver and mammary epithelial cells of rats treated with 7,12-dimethylbenz(a)anthracene, and selective effects of chemopreventive agents. Cancer Res 1999, 59:4285-4290.
27. Flesher JW, Horn J, Lehner AF. Carcinogenicity of 1-hydroxy-3-methylcholanthrene and its electrophilic sulfate ester 1-sulfooxy-3-methylcholanthrene in Sprague-Dawley rats. Biochem Biophys Res Commun 1998, 243:30-35. 10.1006/bbrc.1997.8048, 9473474.
28. Ishikawa K, Takenaga K, Akimoto M, Koshikawa N, Yamaguchi A, Imanishi H, Nakada K, Honma Y, Hayashi J. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 2008, 320:661-664. 10.1126/science.1156906, 18388260.
29. Nioi P, Nguyen T, Sherratt PJ, Pickett CB. The carboxy-terminal Neh3 domain of Nrf2 is required for transcriptional activation. Mol Cell Biol 2005, 25:10895-10906. 10.1128/MCB.25.24.10895-10906.2005, 1316965, 16314513.
30. Pearson KJ, Lewis KN, Price NL, Chang JW, Perez E, Cascajo MV, Tamashiro KL, Poosala S, Csiszar A, Ungvari Z, Kensler TW, Yamamoto M, Egan JM, Longo DL, Ingram DK, Navas P, de Cabo R. Nrf2 mediates cancer protection but not prolongevity induced by caloric restriction. Proc Natl Acad Sci U S A 2008, 105:2325-2330. 10.1073/pnas.0712162105, 2268135, 18287083.
31. Frenkel K, Wei L, Wei H. 7,12-dimethylbenz[a]anthracene induces oxidative DNA modification in vivo. Free Rad Biol Med 1995, 19:373-380. 10.1016/0891-5849(95)00046-Z, 7557552.
32. Soares MP, Bach FH. Heme oxygenase-1: from biology to therapeutic potential. Trends Mol Med 2009, 15:50-58. 10.1016/j.molmed.2008.12.004, 19162549.
33. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009, 9:239-252. 10.1038/nrc2618, 3251309, 19279573.
34. Schafer M, Werner S. Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol 2008, 9:628-638. 10.1038/nrm2455, 18628784.
35. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006, 6:392-401. 10.1038/nrc1877, 16572188.
36. Eyden B, Banerjee SS, Shenjere P, Fisher C. The myofibroblast and its tumours. J Clin Pathol 2009, 62:236-249. 10.1136/jcp.2008.061630, 18930983.
37. Taddei ML, Giannoni E, Raugei G, Scacco S, Sardanelli AM, Papa S, Chiarugi P. Mitochondrial oxidative stress due to complex I dysfunction promotes fibroblast activation and melanoma cell invasiveness. J Signal Transduct 2012, 2012:684592. 3261495, 22272371.
38. Cornil I, Theodorescu D, Man S, Herlyn M, Jambrosic J, Kerbel RS. Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. Proc Natl Acad Sci U S A 1991, 88:6028-6032. 10.1073/pnas.88.14.6028, 52015, 2068080.
39. Shekhar MP, Werdell J, Santner SJ, Pauley RJ, Tait L. Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. Cancer Res 2001, 61:1320-1326.
40. Gorbunova V, Hine C, Tian X, Ablaeva J, Gudkov AV, Nevo E, Seluanov A. Cancer resistance in the blind mole rat is mediated by concerted necrotic cell death mechanism. Proc Natl Acad Sci U S A 2012, 109:19392-19396. 10.1073/pnas.1217211109, 3511137, 23129611.
41. Tian X, Azpurua J, Hine C, Vaidya A, Myakishev-Rempel M, Ablaeva J, Mao Z, Nevo E, Gorbunova V, Seluanov A. High-molecular-mass hyaluronan mediates the cancer resistance of the naked mole rat. Nature 2013, 499:346-349. 10.1038/nature12234, 23783513.
42. Seluanov A, Hine C, Azpurua J, Feigenson M, Bozzella M, Mao Z, Catania KC, Gorbunova V. Hypersensitivity to contact inhibition provides a clue to cancer resistance of naked mole-rat. Proc Natl Acad Sci U S A 2009, 106:19352-19357. 10.1073/pnas.0905252106, 2780760, 19858485.
43. Simpson MA, Lokeshwar VB. Hyaluronan and hyaluronidase in genitourinary tumors. Front Biosci 2008, 13:5664-5680. 2630716, 18508614.
44. Liang S, Mele J, Wu Y, Buffenstein R, Hornsby PJ. Resistance to experimental tumorigenesis in cells of a long-lived mammal, the naked mole-rat (Heterocephalus glaber). Aging Cell 2010, 9:626-635. 10.1111/j.1474-9726.2010.00588.x, 20550519.
45. Desjardins LM, MacManus JP. An adherent cell model to study different stages of apoptosis. Exp Cell Res 1995, 216:380-387. 10.1006/excr.1995.1048, 7843282.
46. Kim JW, Evans C, Weidemann A, Takeda N, Lee YS, Stockmann C, Branco-Price C, Brandberg F, Leone G, Ostrowski MC, Johnson RS. Loss of fibroblast HIF-1alpha accelerates tumorigenesis. Cancer Res 2012, 72:3187-3195. 10.1158/0008-5472.CAN-12-0534, 22556263.
47. Poon E, Harris AL, Ashcroft M. Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Rev Mol Med 2009, 11:e26.
48. Vile GF, Basu-Modak S, Waltner C, Tyrrell RM. Heme oxygenase 1 mediates an adaptive response to oxidative stress in human skin fibroblasts. Proc Natl Acad Sci U S A 1994, 91:2607-2610. 10.1073/pnas.91.7.2607, 43418, 8146161.
49. Nevo E. Mosaic Evolution of Subterranean Mammals: Regression, Progression and Global Convergence 1999, Oxford, UK: Oxford University Press.
50. Malins DC, Anderson KM, Gilman NK, Green VM, Barker EA, Hellstrom KE. Development of a cancer DNA phenotype prior to tumor formation. Proc Natl Acad Sci U S A 2004, 101:10721-10725. 10.1073/pnas.0403888101, 490001, 15249662.
51. Slaga TJ, Gleason GL, Hardin L. Comparison of the skin tumor initiating activity of 3-methylcholanthrene and 3,11-dimethylcholanthrene in mice. Cancer Lett 1979, 7:97-102. 10.1016/S0304-3835(79)80102-0, 476615.
52. Glaysher S, Cree IA. Isolation and culture of colon cancer cells and cell lines. Cancer Cell Culture 2011, 135-140. Portsmouth, UK: Humana Press, Cree IA, 2.
53. Manov I, Hirsh M, Iancu TC. N-acetylcysteine does not protect HepG2 cells against acetaminophen-induced apoptosis. Basic Clin Pharmacol Toxicol 2004, 94:213-225.
54. Tyan SW, Kuo WH, Huang CK, Pan CC, Shew JY, Chang KJ, Lee EY, Lee WH. Breast cancer cells induce cancer-associated fibroblasts to secrete hepatocyte growth factor to enhance breast tumorigenesis. PLoS One 2011, 6:e15313. 10.1371/journal.pone.0015313, 3020942, 21249190.
55. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012, 9:671-675. 10.1038/nmeth.2089, 22930834.
56. Manov I, Hirsh M, Iancu TC. Acetaminophen hepatotoxicity and mechanisms of its protection by N-acetylcysteine: a study of Hep3B cells. Exp Toxicol Pathol 2002, 53:489-500. 10.1078/0940-2993-00215, 11926292.